Delving into the Latest Updates on ConjuChem LLC with Synapse

Overview

Tags

Immune System Diseases

Endocrinology and Metabolic Disease

Infectious Diseases

Biological products

Hormone

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Endocrinology and Metabolic Disease	1
Infectious Diseases	1
Immune System Diseases	1

Top 5 Drug Type	Count

Hormone	1
Biological products	1

Top 5 Target	Count

INSR(Insulin receptor)	1

BACKGROUNDGlucagon-like peptide-1 (GLP-1) mimetics are widely used for treating type 2 diabetes (T2D) with pleiotropic effects on heart and kidneys. The safety/tolerability and pharmacokinetics/pharmacodynamics ((PK/PD) of CJC-1134-PC (a long-acting GLP-1) were investigated in Chinese.METHODTwo randomized, double-blind, placebo-controlled phase I studies were conducted. Study A: 30 healthy subjects received (subcutaneously injected) a single dose (2 mg) or titrate doses (2 + 3 and 2 + 3 + 4 mg at weekly intervals) of CJC-1134-PC. Study B: 49 T2D subjects received 10 weekly doses (1, 2, 3, and 4 mg).RESULTCJC-1134-PC was well tolerated with gastrointestinal (GI) side effects. Higher doses increased the adverse events risk. CJC-1134-PC was steadily absorbed, with maximum plasma concentrations(C_max) occurring at 36-72 h and 48 h after administration in healthy and T2D subjects, respectively. The steady-state exposures in T2D subjects increased more than the dose-proportionality(1-3 mg). The mean t_1/2 ranged from 111.6 to 127.6 h. After four- five weeks of targeting doses, steady state was reached in T2D subjects with apparent accumulation effect. At week 11 for T2D subjects, HbA1c mean baseline change was significantly different than that of the placebo, and the fasting plasma glucose (FPG) was not significantly altered.CONCLUSIONThe safety and PK/PD profiles of weekly CJC-1134-PC doses support Phase II studies with guidance on optimal-dose selection. Clinical trial registration: ChiCTR-IPC-15007190.

100 Deals associated with ConjuChem LLC

Login to view more data

100 Translational Medicine associated with ConjuChem LLC

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 02 Feb 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

2

5

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

DAC HIV(ConjuChem LLC)	HIV Infections More	Preclinical
PC-DAC Insulin(CONJUCHEM, LLC) ( INSR )	Diabetes Mellitus More	Preclinical
CJC-1131 ( GLP-1R )	Diabetes Mellitus, Type 2 More	Discontinued
CJC-1004 ( thrombin )	Thrombosis More	Discontinued
CCI-1008 ( Opioid receptors )	Pain, Postoperative More	Discontinued